Overview
- Australia’s immunisation advisory warns that counterfeit Abhayrab may have circulated in India since late 2023 and urges replacement doses for people treated there from November 2023 who may have received the brand.
- US and UK health agencies issued related alerts, with the CDC reporting a rabies case in a traveler from India and UK authorities conducting a look‑back to identify potentially affected patients.
- Indian Immunologicals says the concern stems from a single counterfeit packaging incident involving batch KA24014 identified in January 2025, which it reported to regulators, and it has asked Australia to revise its advisory.
- Authorities conducted raids in multiple cities and, according to reports, government lab testing found the seized vials contained genuine product with tampered outer packs, indicating possible diversion from public supply.
- India Today reports no public-facing alert from the national drug regulator or the manufacturer, while experts warn that broad warnings may fuel hesitancy and note that standard multi‑dose regimens with immunoglobulin typically still confer protection.